InterVene’s Recana Thrombectomy Catheter System Treats Venous ISR in FIH Procedure

July 22, 2025—InterVene, Inc., a developer of interventional devices for venous inflow and outflow obstructions, announced that the first-in-human (FIH) procedure with its Recana thrombectomy catheter system was performed for treatment of venous in-stent restenosis (ISR).

The patient in the FIH procedure was treated by consultant interventional radiologist Gerry O’Sullivan, MD, at University Hospital Galway in Galway, Ireland.

According to the company, the Recana system is a fully integrated mechanical thrombectomy system designed to address the long-term complications of venous disease, including ISR and native vein obstructions. Recana is an investigational device for use exclusively for clinical investigations.

“The long-term sequelae of venous obstructions, whether in-stent or native vessel, are a devastating consequence of deep venous thrombotic disease,” commented Dr. O’Sullivan in the InterVene press release. “There remains a considerable gap in effective interventional treatments for physicians and their patients living with persistent symptoms related to venous outflow obstructions.”

Dr. O’Sullivan continued, “I had previously tried and failed to recanalize this patient’s vessels on four separate occasions—Recana succeeded in just one. This technology offers real promise for patients with limited treatment options.”

InterVene noted that the FIH procedure was a result of a collaboration between the company and the University of Galway’s Institute of Clinical Trials. Fidelma Dunne, MD, is director of the institute.

“We are proud to see Recana become one of the first innovations to enter clinical use in Ireland through the Hypercare initiative,” stated Dr. Dunne. “This FIH procedure reflects Hypercare’s core mission to streamline the clinical trial process and accelerate patient access to breakthrough therapies.”